140 related articles for article (PubMed ID: 12715164)
1. p53 expression and resistance against paclitaxel in patients with metastatic breast cancer.
Schmidt M; Bachhuber A; Victor A; Steiner E; Mahlke M; Lehr HA; Pilch H; Weikel W; Knapstein PG
J Cancer Res Clin Oncol; 2003 May; 129(5):295-302. PubMed ID: 12715164
[TBL] [Abstract][Full Text] [Related]
2. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
Duman BB; Sahin B; Acikalin A; Ergin M; Zorludemir S
J BUON; 2013; 18(1):44-50. PubMed ID: 23613387
[TBL] [Abstract][Full Text] [Related]
3. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer.
Konecny GE; Thomssen C; Lück HJ; Untch M; Wang HJ; Kuhn W; Eidtmann H; du Bois A; Olbricht S; Steinfeld D; Möbus V; von Minckwitz G; Dandekar S; Ramos L; Pauletti G; Pegram MD; Jänicke F; Slamon DJ
J Natl Cancer Inst; 2004 Aug; 96(15):1141-51. PubMed ID: 15292386
[TBL] [Abstract][Full Text] [Related]
4. Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer.
Van Poznak C; Tan L; Panageas KS; Arroyo CD; Hudis C; Norton L; Seidman AD
J Clin Oncol; 2002 May; 20(9):2319-26. PubMed ID: 11981003
[TBL] [Abstract][Full Text] [Related]
5. Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer.
Formenti SC; Spicer D; Skinner K; Cohen D; Groshen S; Bettini A; Naritoku W; Press M; Salonga D; Tsao-Wei D; Danenberg K; Danenberg P
Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):397-405. PubMed ID: 11872285
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806.
Rincon M; Broadwater G; Harris L; Crocker A; Weaver D; Dressler L; Berry D; Sutton L; Michaelson R; Messino M; Kirshner J; Fleming G; Winer E; Hudis C; Appel S; Norton L; Muss H;
Breast Cancer Res Treat; 2006 Dec; 100(3):301-8. PubMed ID: 16773437
[TBL] [Abstract][Full Text] [Related]
7. Expression of p53, glutathione S-transferase-pi, and Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer.
Silvestrini R; Veneroni S; Benini E; Daidone MG; Luisi A; Leutner M; Maucione A; Kenda R; Zucali R; Veronesi U
J Natl Cancer Inst; 1997 May; 89(9):639-45. PubMed ID: 9150188
[TBL] [Abstract][Full Text] [Related]
8. A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923.
Hamilton A; Larsimont D; Paridaens R; Drijkoningen M; van de Vijver M; Bruning P; Hanby A; Houston S; Treilleux I; Guastalla JP; Van Vreckem A; Sylvester R; Piccart M
Clin Breast Cancer; 2000 Oct; 1(3):233-40; discussion 241-2. PubMed ID: 11899648
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer.
Paradiso A; Mangia A; Chiriatti A; Tommasi S; Zito A; Latorre A; Schittulli F; Lorusso V
Ann Oncol; 2005 May; 16 Suppl 4():iv14-19. PubMed ID: 15923415
[TBL] [Abstract][Full Text] [Related]
10. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.
Kandioler-Eckersberger D; Ludwig C; Rudas M; Kappel S; Janschek E; Wenzel C; Schlagbauer-Wadl H; Mittlböck M; Gnant M; Steger G; Jakesz R
Clin Cancer Res; 2000 Jan; 6(1):50-6. PubMed ID: 10656431
[TBL] [Abstract][Full Text] [Related]
11. Potential predictive factors for response to weekly paclitaxel treatment in patients with metastatic breast cancer.
Sezgin C; Karabulut B; Uslu R; Sanli UA; Goksel G; Zekioglu O; Ozdemir N; Goker E
J Chemother; 2005 Feb; 17(1):96-103. PubMed ID: 15828451
[TBL] [Abstract][Full Text] [Related]
12. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas.
van der Zee AG; Hollema H; Suurmeijer AJ; Krans M; Sluiter WJ; Willemse PH; Aalders JG; de Vries EG
J Clin Oncol; 1995 Jan; 13(1):70-8. PubMed ID: 7799045
[TBL] [Abstract][Full Text] [Related]
13. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.
Berry DA; Muss HB; Thor AD; Dressler L; Liu ET; Broadwater G; Budman DR; Henderson IC; Barcos M; Hayes D; Norton L
J Clin Oncol; 2000 Oct; 18(20):3471-9. PubMed ID: 11032587
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
Sjöström J; Blomqvist C; Heikkilä P; Boguslawski KV; Räisänen-Sokolowski A; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Bergh J; Wist E; Valvere V; Saksela E
Clin Cancer Res; 2000 Aug; 6(8):3103-10. PubMed ID: 10955790
[TBL] [Abstract][Full Text] [Related]
15. Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel.
Fujita T; Ito K; Izumi H; Kimura M; Sano M; Nakagomi H; Maeno K; Hama Y; Shingu K; Tsuchiya S; Kohno K; Fujimori M
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8837-44. PubMed ID: 16361573
[TBL] [Abstract][Full Text] [Related]
16. Human breast cancer susceptibility to paclitaxel therapy is independent of Bcl-2 expression.
Poelman SM; Adeyanju MO; Robertson MA; Recant WM; Karrison T; Fleming GF; Olopade OI; Conzen SD
Clin Cancer Res; 2000 Oct; 6(10):4043-8. PubMed ID: 11051254
[TBL] [Abstract][Full Text] [Related]
17. Drug resistance gene expression and chemotherapy sensitivity detection in Chinese women with different molecular subtypes of breast cancer.
Zhao J; Zhang H; Lei T; Liu J; Zhang S; Wu N; Sun B; Wang M
Cancer Biol Med; 2020 Nov; 17(4):1014-1025. PubMed ID: 33299650
[TBL] [Abstract][Full Text] [Related]
18. Expression of S100A4 and Met: potential predictors for metastasis and survival in early-stage breast cancer.
Lee WY; Su WC; Lin PW; Guo HR; Chang TW; Chen HH
Oncology; 2004; 66(6):429-38. PubMed ID: 15452371
[TBL] [Abstract][Full Text] [Related]
19. Serum HER-2/neu as a prediction and monitoring parameter in a phase II study with weekly paclitaxel in metastatic breast cancer.
Lüftner D; Henschke P; Flath B; Akrivakis C; Schnabel S; Prinz B; Geppert R; Wernecke KD; Possinger K
Anticancer Res; 2004; 24(2B):895-906. PubMed ID: 15161043
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
